Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQUTVWQ2ZBOVFlRnBfeUwxRG5CRUU3ZU1vYk44NXE2TVUweHYyY2FsTkJuck5vdXJHa21RemQweEVibDJ3N2NSZkkxOVNuVVN0TUU5TTR0RjZyQkYwbnZSd3B4VTdmZHB5T0MtbEN5LWxhUlN4cVc2aVRKdHEtOVB6dVFxYTBPZHFCTGZxWUI4Z3ptSTdoYi12TkRRdzJ5SEd3RlpjV1J6SEJ2cGM?oc=5" target="_blank">Accelerating and Modernizing Early and Late-Stage Clinical Development</a>&nbsp;&nbsp;<font color="#6f6f6f">U.S. Food and Drug Administration (.gov)</font>
Premier League LIVE: Coventry City vs Newcastle United - build-up, team news, score, text commentary & match stats
Levante - Sevilla en directo
"La cosa se está poniendo tensa": manifestantes se enfrentan a agentes migratorios en Oregon
Indigo Girls cancel show after tour bus driver dies in highway crash
Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFBxZGE0QU9vQ2ViMlViM3NtZ2F2Mk9TNkRaUC1WRHBJcENaNEJvX0FfeWhCeGVOeDhSMEhXZzZ3XzY0SDdxTXdsNWFteFAwUTl5YVZXRzlFcDBvQ2M3Q3hQNXpmUWJPNG5ONWZXZ210dDNEN25wTW1n?oc=5" target="_blank">FDA's IND Pilot Puts CMC Review First</a>&nbsp;&nbsp;<font color="#6f6f6f">PharmTech.com</font>
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxQaDk2MlEwRFQ2MklZYW11OWNPbXpwRkpvUURYTHF6WjRRQURnaE1laXRvTmd0SnNmUllaWWRXckVqZldvbjFzQkl5Sk14VXVFdDVBUVpPYmVxSGdhZ1ozbWtISzh4MFY2VWFwME1HamZSbUVXSXJPUUxYM1NNVmlKNk55MA?oc=5" target="_blank">Insilico’s Rentosertib Inhalation Solution Receives IND Clearance for the World’s First AI-Driven Candidate to Enter Direct-to-Lung Clinical Study</a>&nbsp;&nbsp;<font color="#6f6f6f">Insilico Medicine</font>
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxNdUlCamJkZURkcVgtZFlqZi0zWHNVSUFwcndSWWx3SkpVaEJEUXh2NU5PZm9falZlQS03SktoNUZRWXNDb1RYRFNrN3YyUHRPYXlfdEJ0R3Nud0JNX0Y0bk4tcHNrdlRqakhkVS14WjJ0enFSVGg0TGk2Sk9nN2kyeGpEOVJDWGNnYU8yV1NaSGdXSlBWcHdiRlBSVWxwel9PYVQyczk1bllPQmRab1h4WVpLWXBQZmthN19PV0h6bEx2N1U?oc=5" target="_blank">Life Biosciences Announces FDA Clearance of IND Application for ER-100 in Optic Neuropathies</a>&nbsp;&nbsp;<font color="#6f6f6f">Life Biosciences</font>
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOblNiMXNzZzhVcUhnYmt5RHpGTG1YU0xmLTk0UEYwU1hiX21fQ3Y4clRpeHJfaXNDTWpaR0xqVVdjYWZaZkpwakY2U0xQNGNjY2U0WWhUc3NIaE5WeVdEeDNaU0doZXhZUnRrenQwRzgxaDIxeXpQR3FpYUFTSVU2eGJjNXltX0Z1YXFoMEFwbjkyV2VReGc1bUxTWEp5ZjlBOTFEdXNvZ3Vpc2JoYTJBZzVMZk1EQQ?oc=5" target="_blank">FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMi_gFBVV95cUxNUDdXaWdMNUIwTEFveEk4T0NwRmc3Q2ZiNEhJajFCZWpDZUx6cnY4UmFqdDR4MElZRXFvYzh4aWduQkhoTVd4Wl9GYkFWdlJKUlR5a0ItaE5PMzNVa09yRmdjM09SSExXckNTeVpXcVlPai1zSk5zMmlRSlEyTVk2VjhUaTJ4STdmVFZ2bjJaYjlidjVrdXo2UU9sWl9FVUFzV1dVNjBOWG1SUEctcFNjUF9HWWNOcUZmTFAxY0d5NGZCM1QwbTJCbVZmQ0JDeG5vcjJBTUxFZVAwdTFNWTZkVFp0Si1OU3FFWEtQLWpreGJPb1lzQkhlRnptYVJlUQ?oc=5" target="_blank">SMSbiotech Receives FDA "Study May Proceed" Notification for First U.S. IND-Cleared Inhaled Stem Cell Therapy in COPD</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOdjNTZ2lxaUtvY1V4UjFSZ0hiSUpXcjE1WW5WVVpXVkZYTmkzNldldnZGZ21TajlLbGhuZThIU0JUbmVlMDZBQTRjcEdrZ1RvRnZqejMzcUxkU1U2cWpxSGt2eE5lY0x0bUNzOFM2ZGNXc0s2SE9Rei13MWJvOXVRYk9BNHBUUkZPc3djczFnZDNNdjZ4cWFIQkxPT09oMzgwdlV4MUZROGlad05KT2Voa2lWaEc2V3NzeWpuaEMtcTg?oc=5" target="_blank">Humacyte Plans First Human Study of Bioengineered Vessel in Heart Bypass</a>&nbsp;&nbsp;<font color="#6f6f6f">Stock Titan</font>
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxOeDRxdkNyZWhLc1p2YngySjBSMC1hY05fdlNOZ0pPN2JvZ0w0Um1DN0Y0MnZfWllsWHBfWG1aSFJLWEVBTGdBQTNXRllPZnJsaXlUU1ZlVXZXdXFsQ0o2UTR3M1BCb29qckFuVE1fTTFuNTF0SFFwcXNRcGxSNTAzaGhGdzB1d2FZUFM5NUJqWS1aR2E3QU5XVHVxNTBaRG5SWmJUa0RROXhxZ19yV1JfUUdRRkF3SWhqVXkwVklTVFQ5Z1EtLVlIeVBR?oc=5" target="_blank">Humacyte wins FDA IND clearance for first-in-human CTEV study in coronary artery bypass grafting</a>&nbsp;&nbsp;<font color="#6f6f6f">Dealroom</font>
<a href="https://news.google.com/rss/articles/CBMi0gJBVV95cUxNWGgtQ1FjTXFRakZhUGp2UXR1OWdYdWdDVkV4YWMxbXZieGg5Sm4ydmUwb3AzTzN1RnJ0aENKUk1QbGhVeHA4SVRtTkRQT3ZRRGZDMTg5SERGTk5oQzJkdS1CZWlkMGFOWURzdkYzVGlCUE5PRlAyY1M4ZTNKa3pON0p5SmNyQUJsQkE1Smp6YjRsdlowMW1reWxUVUxDVlJkTGtHUHZUZi1xeUF1MGNkcTZ0OHBLNDItNkh1Ymp0MmQwTVhPeDJRc09vM0dwUVdnSWl4TVN1dW5CRnA2V1BvaVhBWi1lVmk4MUk1dVJXUkd4aXVsY2pCaTFzbVBxN1N4YjRmSUxLTkFJQ3ZHemN0b2VRWDRlNHZ0b0hqTFRaUFpkN2Mya2Q4THBkMmxucXlscUNPMFR2NDVaeC1lb0V5ZFQ2WWl0MmF6RHV4RmpNX28xUQ?oc=5" target="_blank">Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study</a>&nbsp;&nbsp;<font color="#6f6f6f">GlobeNewswire</font>
<a href="https://news.google.com/rss/articles/CBMiswJBVV95cUxPQmxEQjhWd3lUSXBteWszQkU2WE1ZQmc5UzVtUUlkZk5ZZ0o4YVMwZ1JhQlJmcjFnSGZvbnZxVXR6Y1BKRTV1M24zVlUzVG12WmFfUnlKeXBBd2R0VURiR19IYmJDbEExYVJlR0VySUxFWlVfNTg2QzJjMEpjczI0OWRJVEhTMTFQN3FXaS1VcmNJSFNWUUtob0FZMnBqMmpBOGtlSnRiZGdYa3lFVTJzLXRFVDN3LVo2MjdQZ25PZ29sVFJ2NVF5WG93OWVVTXliNTQ2OUJudXlvS1lPU2s1NHBibzdVaWRGcTh3RkpCb2RIa19uUkxrRlhWU2ZlTmJ5SS1idmZOdmU3MHdSR1VQdEFKcUd0VEJpb0xrRE1JVkpxQU9nbU5ERjcza1hFSGE5WTc4?oc=5" target="_blank">Arialys Therapeutics Announces First ANRE Patient Treated with ART5803 in Open-Label Phase 2 Study and FDA Clearance of IND for Randomized Phase 2 Study</a>&nbsp;&nbsp;<font color="#6f6f6f">Business Wire</font>
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxQRjBwM3ZwQUozWUJzNUNNeW5hSkhYbHlrcWJxRTVEOTBjaWZPd3B1bmlybFBnalZCdVFYLXV2ZkxqODd3aTNsZTNIekdZTGpTclMzcWZiZ004dnBwMFNnbnc3Y2w2b0lZMU9SYTZtUkdfMTBOZW5jeVMtaHlKTXlKZ1JSYmFrelh6Ul9RZnZn?oc=5" target="_blank">Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS</a>&nbsp;&nbsp;<font color="#6f6f6f">Manufacturing Chemist</font>
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPaVhsSDZMVmh6WDdPTG9hM0VuTkhaY1N0ZEZSUkZkUlhDUy1DSlBMUFAydmRTT3RRQkdlN1YyYWQwUDRUTThoZFVRTGRmMkdhRUFKQy1mRG8xRkVRQUV2X3hfVzlyWTg3Nk1MV2drUkMySnlhbDRsNGhjNFVYQmM0c3F2NF9GUjlseWdpNHBPQkRzVjFITzlEdXpzSVdtdnpaT0VCOGpyZXNla2dlYXJiQmFWNTY1a3pXbDk5cTRpcmFjUWRxaFFoVEU3VU5QbTRwTWJhLXBFZHVaRDUyWnZKOG5RLXZCWWlkbTdQOQ?oc=5" target="_blank">XtalPi Receives Second Payment from DoveTree; First Oncology Asset Advances into IND-Enabling Studies</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPbXhYWDJGd2JUZndnVFVSSEhsVW9xN3E3TWl1T21qenNmdWd0WXNvTkNXdklZYnAyZ0ZiR3NXQ3JyUnF5R0NpVno4akJSQU1HOWZBRlRxTzZBZ0ppdlhCa3pjTFprcXlNYm5NM1FWSUV6eGFDcFJnelhWVEZDTEMxeVhobUhpWGdkbDV4UlRkU3ZzNmp6S1hXYjFna1hSYU55bFBoTjZJell1X2dQ?oc=5" target="_blank">FDA Clears IND for Investigational Program in Recurrent High-Grade Glioma</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.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?oc=5" target="_blank">Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study</a>&nbsp;&nbsp;<font color="#6f6f6f">GlobeNewswire</font>
<a href="https://news.google.com/rss/articles/CBMigwJBVV95cUxNX2NUTUhXdGdpZEhtWVlCbmNiR3dHbkhwVkZzeHloY01fWG5oOVBEbmlrZkNQSlY4NkhaZjRWZUZoTFRJRW5RNjVTTXNQSlo5TzhqVzBxT3NpR05EV0NnUm8ydl81X1VCT1FvcnNmbzBFUFdyYXVsMGNoTUNiUXF4VHlDU0RCX3kzNHpldDAwZ1A4Tm1RQVNQc0FEc0ZpYVlIeklrbzVaaV9FTU5JTGdfaHdFUG1qMDhVbVpXSjl5bWhxS21RN1hJMzQ4SlV2ZXpiY0ctQzVfalc0S2x2YjhOWmJJWU8zSVhxWlc5MEc3NFBkRlVaM0kzbURQcE81cjZoTU9N?oc=5" target="_blank">DemeRx Announces FDA Acceptance of IND Application to Advance DMX-1001 for the Treatment of Alcohol Use Disorder (AUD)</a>&nbsp;&nbsp;<font color="#6f6f6f">Business Wire</font>
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxPaGNDNzVySlNJTXJ4cUlGU0dUbGRwVW54OFZGWmhBZGllWEtEZkFCeW5jdEl1MW5KamJBSVNxRFF6Q1VCSl95THV6RFJoczdTeXlkVTBVemVGMjIxUU51Z0UySGtvTjNabVZfYnFxSXc3aEFrbmRnRDRxSGwxaW1vanZzcU1yZnZLazlDbXdwcVMzbU4wNjQydjVZcmR6dlNJNFQ5aFkxREtaUFA4YTBpUVZFanNPRkxLWDdYSXNUQy1SaVJiT3ViRnNvZ0JnNmRPc3JfR0xzVDlrUUFiX3B2SjBPc3h2emNQUmJhRS13?oc=5" target="_blank">GH Research Reports First Quarter 2026 Financial Results and Provides Business Update</a>&nbsp;&nbsp;<font color="#6f6f6f">GlobeNewswire</font>
<a href="https://news.google.com/rss/articles/CBMi2gJBVV95cUxPOW9oV0ZWZHo3OG1GVEliTWhvaXJzVGJCN0NMZFNvQWZRT0NraVBiZEhvcWo2dU4xTHpEek9DNkplR05zcEpDaF80MWRkUEd4OTVGMURSUEZjOHNmM0FNUFJobC0xZWxmR29JRzlpOE5rM0dYZE5JcFoyRmwzdW4xTjdrckpqSDZSVklxX2c5QlozbkhQbUZRZFJoRWhtTjUxNUFQQURIZmVmdFJ2aEZmN3IzME5JdWpjUXRKaUpZMDlBQlAzS1dHdHVSdHRidW9FOXR5VFVrX2kwV1lsc1h4eUcyZklFQXpGN183R2t2bndIeER1MWsyVF9BM0E2YjFDU21yc1FhSks2ZDM3N1RwMFd5elJHQUtmZHY4R21VYkFSVTc2X1MxN1hoUVNBWTdLQ01iTHd2QWpHeHJXcXh3dElLWHU0YnJMOGo0a0ViV0xEMnN4eUU1dHJ3?oc=5" target="_blank">EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxQY1htWk8yR1BMcmxUOXdVQTV3U2ZBNTJpQnIwSjBZUGxFelVURWZYdEV2elU5ZnRtYUpjd0pSM1VqRjdEMmNqVHJhNmtYWjRpTk92OVZlU1RBRi1oaTBuQ1lLdXhGbUdjV082bGJUcjFiWGRKRGxscUZycE1wbWhhZTNlSkJEZGFpSHVJWmV5OVVlS2dPY3FlSmkzYl9LYThSTVZpSEwwbWM1bWZVNEV0VmR4NkNxUlR5dkIxWnJRTUp4MThrTU1hdlNJS1pSLTAxSlR3ZEQwNjUzMjhTXzJFeHZUZw?oc=5" target="_blank">Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update</a>&nbsp;&nbsp;<font color="#6f6f6f">GlobeNewswire</font>
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxQT1J1eFhLMlVhSUJDdkJKNGF4dTlLajVWd191VC1hdjcxYWVOSnNPbGJTNXo0MF9pRThOWGhKV200Q01xdEFwSjBHTngxcXJvNkd3Z29wdjJTa1NfSHFqSG5Ra1gyU1Mxd0RFbU04dk8xZDk0MWRON2JWOEVsNWJZMnVqYWJQZGZEYkhlVWREbnZwOGR6eUhPTmMwRFpyVk8xOG9zZ3N2NXF3SXZ1MDBULUtZMV9oYTJ5ODNHX2k3cUtGUjlIZm1VeTJsVUtWUDJiTGxMZmRkdmdfVEFnUWxKQU9mV0o?oc=5" target="_blank">aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update</a>&nbsp;&nbsp;<font color="#6f6f6f">GlobeNewswire</font>
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNRk9MaVJhVHZyTzNOemRvaHNmR2Q3emFOYmM1LU5ROElQd2YxMVdwNGl5Y2tjTVRKUG44SWJMS1N3UE4ycDlnbE5hMUFrNHhCM1UxcTZsdWJSRUVGclI2bzBHYkZZRDlEampTWWZQZ2lBVVBXZzg2SGtYckU3ZVN4MnA3X1VXbWdaaU5YbHEzTHhSQndlSmVPUGlDeGNVelhjOGlfZVlqWmxuTWVTS3ZhaVRRR2Nvd0JiVF82SmxfNkR4Zw?oc=5" target="_blank">Trace Biosciences Announces FDA IND Clearance for First Nerve-Specific Imaging Agent</a>&nbsp;&nbsp;<font color="#6f6f6f">BioSpace</font>
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxNc3RHbXpnNkxQVU5KRWtLQ3A3Rko2UlZlR1U5d3hHc1p2ZDJhV1FsQnpFaEN1OVhMZjdIQVMxZHBVUXdXaWpsZk10RExKWVljamU1MFoySXVBazhSN21rbFF3LWlBVTAyanhUbXlUU1FZdVpvdTdpS3JqcS13SUVRcHd5aUk5U2ZZMEhQMUk5aWlkQmpuNnBMV3lwVVBEelVpU2NJU21DX2VqNVduVjF0clUwdUJPSTZfMUR0M1F6dkxMYW1xMnlqajV1bnI?oc=5" target="_blank">Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program</a>&nbsp;&nbsp;<font color="#6f6f6f">Lelezard</font>
<a href="https://news.google.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?oc=5" target="_blank">Enveda Announces US FDA IND Clearance and First Patient Dosed in Phase 1 Trial of ENV-308, a First-in-Class Oral Therapy for Obesity; Appoints Nadeem Sarwar, Ph.D., MPharm, MPhil, to Lead Metabolic Disease Strategy</a>&nbsp;&nbsp;<font color="#6f6f6f">BioSpace</font>
<a href="https://news.google.com/rss/articles/CBMi1wJBVV95cUxNZzU3b3dSa1RxMHNrYUtZTHBHLVZnZy1fd29QTzJuVDVxZVphTGRDd09JYVpxaExYRjY4SEg5SFFVbjFSTUlLN216emFxSDVuVzc5U3ZIMjNiMkFtTGFmZzVtMUpfWV9hWDVQaHZqaUpzZG1rNTBmVU1SZmRjZTB4RnNRYUtPWjc2QmZXcm1WeGJNeWtZcDd3dWZ1N05jQzVWYnA1c1Q3VkRncXdSSC1SS3ItOEU3WjBFTkoxMnJLcXFxbExCY0lTR1Bwem05SUwwU3BUWDllWFBiSUpuVTN5QTZwbWVHTEIyYXMyLUNxZlpkeFJPRG02dUUxNi15SVpLUVNheW5od0lqbUJIRnRualVTclRmOTlMU3pjUWxsMThNbWZtQVlzcDkycjBlTUJfRExGdUZWeWJ0WnFBWS1kWDBOTmlYeDJZZzNQYzZyRmQ2V0JwUHMw?oc=5" target="_blank">VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology in ALS</a>&nbsp;&nbsp;<font color="#6f6f6f">Business Wire</font>
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNYU5keXB5YnJROWcxUlNMLXN2b1JIcTRyZzgwM0xyRThaNEFWN3M0UHIzOTQwZGVnWTNWLXFHSHR2NHRLOU51aWJxX1VDelBvb3IySzRMR0hMcFZmV01IUUREZ2tvS0I5SUxyQ0dPcU9jNWNGWURyX2xRUy1Pd0tiaC12bEtSRDBWQkZ2bFQ0cUo2ck9ISklZUGRMNzREb3BhYVlPWWVod21hRDF0QkVmcHNKY0M0Mkx0QWlBOQ?oc=5" target="_blank">First FDA IND Milestone Achieved Using Human Vascularized Organoid Efficacy Data</a>&nbsp;&nbsp;<font color="#6f6f6f">Fierce Biotech</font>
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxNS2hZNDFtYnlhTGVjX242eld1UmNSQllWc3lON3RJampjRndaNHh5cDlMUUNxbTNiVERRdHNPcExNZER4amVDTmdvMEhnWFpIUGlTZXlTXzNIcDNIY3pxMjVRcmVJMGhtQVRGbVBtcl9sVUJyb3FVU1M0Qlg0WTJyOTdCUQ?oc=5" target="_blank">Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics</a>&nbsp;&nbsp;<font color="#6f6f6f">Insilico Medicine</font>
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNWlRTclFoWmZBTllvdXR5dkhlWHVZVU4zeF9fam1mdlJreG9QOE1RY2FrbWl4VUZhTHQwUmxOUkU4UXJORnExdjQ3a3ZMUURjcmFPYkNVWFBtTWloZTZfck5ib1NVT05DNEdIQlJ0V1I0Q2hLNlNZQUpVU0lILW1HVFVQWTkyanpXaWdPUUF5Z1JLQmQxanJxdA?oc=5" target="_blank">Cell Therapy Weekly: First IND Cleared for AAV-based Cancer Therapy</a>&nbsp;&nbsp;<font color="#6f6f6f">RegMedNet</font>
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxPajlhdkgzNkxUTVdOWWQ1ckZjSFZGTTBmaHFoaUF5WXF3UzFTRXlvRVJnUHE0VHZjTmtRLXBoel8tRDg4SkRCY3ltcmUweDcwSDV0MkhNLXVVRHFhUjVlRmlyWGk3M0xRbmkzVzRNTkIzZU1pZVVLS1lQOVZDRGVILTVLcS12cUw5enM0Ml9jb3QyYkpuMmhVa0tLR3lseElUZWNHdHJ5XzR1VEpDaVB3WHNlNUh4SmJJSmFoN2JxZ284WnMtNGZRUjJTUzQ2MHRZTnAwcXA3SURYVXRPd2JYQmRGME04ZmxobmR2Z2c5VQ?oc=5" target="_blank">Press Release Service: Capsida Receives FDA IND Clearance for Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy</a>&nbsp;&nbsp;<font color="#6f6f6f">CRISPR Medicine News</font>
<a href="https://news.google.com/rss/articles/CBMingJBVV95cUxPblB1emE4c05obmFMMEMyMWxTRHYtVHlKVi10UzdvblJRbks2WEVGRDFTUjhaaDFkOGNxM0lPRHpuT2I1bmhnZVJkOHYzNVFfaWxPMWk0VHZuVUZzQVZrNEp2bmplSEh5YnN1TF9SR2R2ZDdrdlhKTllQRUM4TDZUS0FxZHdTeVhJWVNXSXNVazFpaGMwLVBYSlE0aFNsUVBCbEhNVXd5a2dNcFF0c0FiOU5mMUNnNDF4N2M2bGRkYkFweFdXWnY2N3djMV9fd0EyMVBNVVFNa2JZSzJ2djd2UlNqWkFGVDhnVWtCN0JmUGhHT2M2RXYzN3VBTVJnZnZyWnZFS2xwTTlWN1VqWUdHZEFoOXJ3NnVaVXZ1TTRB?oc=5" target="_blank">IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
<a href="https://news.google.com/rss/articles/CBMiqgJBVV95cUxPX3h0REhtUk1fYjV3WGtHbjVHbDdyQXg2U0pRRFVJdmpfZzhsS3lCUDR4TExHZ1RzMlJCWDNaTkVTU3hsa1NKdTRvYkpta3hhcHFDT013UVk2Q3IzN0Rheld5TmZEUXpBQTVUZVhIR044YzY5NENVUkZUcDhvTGRMWU90VmgxaUF6aU05R3FORU5BNWxvSnNRTmh6RU92aDRkYVFLdmRXdWVfZkplc01JWEFOZURFLWFkUjhSa09xWTJnR1pRbXh4R1h0ZzlRc2xpNXpQWWFvU05WQ0FVek9iSmRYV2FFZkxCODFRZTBmcnJmekxHQjlmY3FISVdYaVRBZVNkR1UxZzFUVXQyOVMtOGw2R1JBMzJPcy1fclRWMm9Gd2NuQ0YzLWp3?oc=5" target="_blank">IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5yUWZPVkJHVFhCR2ItdXRKZjZIRjh0VmhrSGlQTWtudEpjN0xLakI5akVSalJBcWRMS1FZWlNZa0N0Y3FRbDFyemJVUm1vRUMtQXcxWGI1a0l6TUxjSzRr?oc=5" target="_blank">First insight into metal binding proteins from the de novo transcriptome of acanthocephalan parasite Dentitruncus truttae</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>